News
LKFT
28.94
+2.26%
0.64
Weekly Report: what happened at LKFT last week (0615-0619)?
Weekly Report · 22h ago
Lakefront Biotherapeutics Details June Share Buybacks Under New Repurchase Program
TipRanks · 6d ago
Lakefront Biotherapeutics Repurchases 38,537 Of Its Own Shares Through June 9 - June 12
Benzinga · 6d ago
Weekly Report: what happened at LKFT last week (0608-0612)?
Weekly Report · 06/15 09:44
Fine Foods completes acquisition of Sofar from Alfasigma for EUR 23.4 million
PUBT · 06/12 09:57
Lakefront Biotherapeutics launches €50M share buyback program
Seeking Alpha · 06/09 20:14
Lakefront Biotherapeutics announces EUR 50M share repurchase program
TipRanks · 06/09 20:13
Lakefront Biotherapeutics launches EUR 50 million share buyback program
PUBT · 06/09 20:01
LAKEFRONT ANNOUNCES INITIATION OF €50 MILLION STOCK REPURCHASE PROGRAM
Reuters · 06/09 20:01
Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer
TipRanks · 06/08 20:13
Lakefront Biotherapeutics names Eric Hedrick chief medical officer
PUBT · 06/08 20:01
Weekly Report: what happened at LKFT last week (0601-0605)?
Weekly Report · 06/08 09:41
Lakefront Biotherapeutics and Gilead Close Ouro Medicines Deal, Anchor Autoimmune Pipeline Around Gamgertamig
TipRanks · 06/05 10:29
Gilead, Lakefront complete Ouro Medicines acquisition
Seeking Alpha · 06/04 20:59
Gilead, Lakefront complete Ouro Medicines acquisition for USD 1.68 billion
PUBT · 06/04 20:16
Weekly Report: what happened at LKFT last week (0525-0529)?
Weekly Report · 06/01 09:44
Lakefront Biotherapeutics Discloses Bank of America Building 9.3% Stake
TipRanks · 05/27 10:29
Lakefront Biotherapeutics Says Bank Of America Raised Its Stake To 9.3% Through Voting Rights And Financial Instruments
Benzinga · 05/26 20:04
LAKEFRONT RECEIVES TRANSPARENCY NOTIFICATION FROM BANK OF AMERICA
Reuters · 05/26 20:02
Bank of America lifts Lakefront Biotherapeutics stake to 9.3%
PUBT · 05/26 20:01
More
Webull provides a variety of real-time LKFT stock news. You can receive the latest news about Lakefront Biotherapeutics NV through multiple platforms. This information may help you make smarter investment decisions.
About LKFT
Lakefront Biotherapeutics NV is a Belgium‑based company. The Company develops medicines for patients with serious diseases in areas of unmet medical need and uses deal‑making capabilities and capital to identify, acquire, and advance opportunities that create value for patients and shareholders. Its pipeline includes clinical‑stage immunology and oncology programs, such as autoimmune disease candidates and selected oncology assets, primarily advanced through partnerships and targeted development rather than in‑house cell therapy platforms. It builds a portfolio of clinical‑stage therapies intended to support existing treatment approaches and operates across oncology and immunology and inflammation programs supported by clinical proof of concept in emerging therapeutic areas.